Plain-English translation of NCT06976216 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Alzheimer's Disease research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether a new medication called + can help improve memory and thinking skills in people with mild to moderate Alzheimer's disease. About 586 people will join the study, and roughly half will receive the new medication while the other half receives a placebo (a pill with no active ingredient). Researchers will compare how well the medication works compared to placebo and monitor how safe it is.
Alzheimer's disease causes memory loss and difficulty thinking that gets worse over time, and current treatments have limited benefits. This trial is testing whether this medication might help slow or improve these cognitive problems in people with early-stage Alzheimer's disease.
You likely qualify if…
You likely don't qualify if…
If you join, you will be randomly assigned to take either the new medication or a placebo, and neither you nor the research team will know which one you are receiving. You will visit the clinic for appointments to receive the medication, complete memory and thinking tests, and have your health monitored. Your caregiver will need to attend visits with you and help track how you are doing throughout the study.
AI-generated summary from trial data · Jun 28, 2026 · Not medical advice
United States